Anne-Marie Koop

176 23. Gupte AA, Cordero-Reyes AM, Youker KA, Matsunami RK, Engler DA, Li S, Loebe M, Ashrith G, Torre-Amione G, Hamilton DJ. Differential Mitochondrial Function in Remodeled Right and Nonremodeled Left Ventricles in Pulmonary Hypertension. J Card Fail D.J. Hamilton, Houston Methodist Hospital and Research Institute, Houston, United States; 2016;22:73–81. 24. Buermans HPJ, Redout EM, Schiel AE, Musters RJP, Zuidwijk M, Eijk PP, Hardeveld C Van, Kasanmoentalib S, Visser FC, Ylstra B, Simonides WS. Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure. Physiol Genomics W.S. Simonides, Laboratory for Physiology, Institute for Cardiovascular Research (ICaR-VU), VU Univ. Medical Center, 1081 BT Amsterdam, Netherlands; 2005;21:314–323. 25. Nagaya N, Goto Y, Satoh T, Uematsu M, Hamada S, Kuribayashi S, Okano Y, Kyotani S, Shimotsu Y, Fukuchi K, Nakanishi N, Takamiya M, Ishida Y. Impaired regional fatty acid uptake and systolic dysfunction in hypertrophied right ventricle. J Nucl Med Y. Goto, Division of Cardiology, Department of Medicine, National Cardiovascular Center, Suita, Osaka 565, Japan; 1998;39:1676–1680. 26. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation - A novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta - Mol Cell Res Elsevier B.V.; 2011;1813:1333–1350. 27. Fillmore N, Lopaschuk GD. Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim Biophys Acta - Mol Cell Res Elsevier B.V.; 2013;1833:857–865. 28. Ashrafian H, Neubauer S. Metabolic modulation in heart failure: High time for a definitive clinical trial. Heart 2011;97:267–268. 29. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280–3288. 30. Revenco D, Morgan JP. Metabolic modulation and cellular therapy of cardiac dysfunction and failure. J Cell Mol Med 2009;13:811–825. 31. Borgdorff MA, Koop AM, Bloks VW, Dickinson MG, Steendijk P, Sillje HH, Wiechen MP van, Berger RM, Bartelds B. Clinical symptoms of right ventricular failure in experimental chronic pressure load are associated with progressive diastolic dysfunction. J Mol Cell Cardiol 2015;79:244–253. 32. Herzog K, Pras-Raves ML, Vervaart MAT, Luyf ACM, Kampen AHC van, Wanders RJA, WaterhamHR, Vaz FM. Lipidomic analysis of fibroblasts fromZellweger spectrum disorder patients identifies disease-specific phospholipid ratios. J Lipid Res 2016;57:1447–1454. 33. HoutkooperRH, RodenburgRJ,ThielsC, LentheHvan, Stet F, Poll-TheBT, StoneJE, Steward CG, Wanders RJ, Smeitink J, KulikW, Vaz FM. Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography- mass spectrometry as a diagnostic test for Barth syndrome. Anal Biochem Elsevier Inc.; 2009;387:230–237. 34. Yu L, Ruifrok WPT, Meissner M, Bos EM, Goor H Van, Sanjabi B, Harst P Van Der, Pitt B, Goldstein IJ, Koerts JA, Veldhuisen DJ Van, Bank RA, Gilst WH Van, Silljé HHW, Boer RA De. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Hear Fail 2013;6:107–117.